A Phase 2, Multicenter, Randomized Open-Label Study to Determine the Efficacy of Lenalidomide (Revlimid) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma.

Trial Profile

A Phase 2, Multicenter, Randomized Open-Label Study to Determine the Efficacy of Lenalidomide (Revlimid) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Chlorambucil; Cytarabine; Fludarabine; Fludarabine; Gemcitabine; Rituximab
  • Indications Mantle-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SPRINT
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 30 Nov 2017 Planned End Date changed from 7 Dec 2017 to 28 Mar 2018.
    • 30 Nov 2017 Planned primary completion date changed from 7 Dec 2017 to 28 Mar 2018.
    • 01 Nov 2017 Results investigating mechanism of action of lenalidomide published in the British Journal of Haematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top